“There is finally some encouraging news for the millions of people suffering from Alzheimer’s disease (AD). NeuroEM Therapeutics, headquartered in Phoenix, Arizona, has announced findings from an open-label clinical trial showing reversal of cognitive impairment in Alzheimer’s disease patients after just two months of treatment using the company’s wearable head device for in-home treatment.
The results demonstrate that Transcranial Electromagnetic Treatment (TEMT) was safe in all eight participating patients with mild to moderate AD and led to enhanced cognitive performance in seven of them, as measured by their ADAS-cog score, a benchmark for testing AD therapeutics. The study is published in the Journal of Alzheimer’s Disease…”
Read More: https://www.futuretimeline.net/blog/2019/09/23.htm